减值拖累业绩变脸 仙乐健康陷转型阵痛与结构分化

Core Viewpoint - Xianle Health is expected to report a significant decline in net profit for 2025, with estimates ranging from 101 million to 151 million yuan, representing a year-on-year drop of 53% to 69%. The non-recurring net profit is projected to decrease by 74% to 82%, amounting to between 57.5 million and 85.97 million yuan. This performance shift is attributed to multiple factors, including non-core business losses, strategic investments, and changes in the industry environment [1][6]. Financial Performance Overview - From 2022 to 2024, Xianle Health's revenue grew from 2.507 billion yuan to 4.211 billion yuan, with year-on-year growth rates of 5.84%, 42.87%, and 17.56% respectively. Net profit increased from 212 million yuan to 325 million yuan, with year-on-year growth rates of -8.43%, 32.39%, and 15.66% [1][6]. - In the first three quarters of 2025, the company reported revenue of 3.291 billion yuan, a year-on-year increase of 7.96%, and a net profit of 260 million yuan, up 8.53%, indicating that the significant decline is primarily concentrated in the fourth quarter of 2025 [1][6]. Causes of Profit Decline - The core reason for the profit decline in 2025 is the ongoing losses in the personal care business and related asset impairment provisions. The operational environment for this segment has deteriorated since 2025, with decreased customer demand and increased operational costs due to intensified US-China trade tensions. Additionally, team changes in the second half of 2025 exacerbated operational difficulties, leading to increased losses and significant declines in revenue and gross profit [2][7]. - The company has decided to divest the personal care segment to focus on its core business and enhance overall profitability, resulting in an asset impairment loss of 194.9587 million yuan [2][7]. Strategic Investments and Challenges - Xianle Health has initiated strategic consulting projects in 2025, incurring high one-time consulting fees. The company is also investing in emerging sectors such as precision nutrition and pet nutrition, but these investments have not yet yielded benefits to offset the profitability pressures from both core and non-core businesses [3][8]. - The investment impairment related to Hubei Yibenhui also impacted performance, with a provision for investment impairment loss of 56.5473 million yuan due to unmet performance expectations [3][8]. Business Structure and Market Dynamics - The company’s business structure has undergone significant changes, with domestic revenue declining from 1.491 billion yuan in 2022 to 1.66 billion yuan in 2024, a year-on-year drop of 10.28%. The first half of 2025 continued this downward trend, with revenue of 818 million yuan, down 1.63% year-on-year. This shift is attributed to changing consumer trends in the domestic health product market, with new e-commerce brands and cross-border e-commerce brands gaining market share [4][9]. - To adapt to domestic market changes, Xianle Health has accelerated adjustments to its customer structure and channel layout, with a notable recovery in domestic business growth by the third quarter of 2025, where strategic key account customer revenue grew nearly 30% year-on-year [5][10]. Global Expansion and Risks - Since 2016, Xianle Health has pursued a global expansion strategy, acquiring companies like Germany's Ayanda and the US's Best Formulations, resulting in rapid growth in overseas revenue from 1.016 billion yuan to 2.55 billion yuan from 2022 to 2024. However, growth in the first half of 2025 slowed to 5.58%, indicating challenges in the international market as well [5][10]. - The CDMO model presents inherent risks, requiring substantial upfront investment in research and process validation to secure long-term customer orders. The current shortening of the product life cycle in the domestic health product market, from 18 months to less than 9 months, complicates the amortization of these initial investments, potentially impacting overall profitability [10].